Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Feb 22 2018

Full Issue

Sweeping Study Settles Hot Debate Over Whether Antidepressants Even Work, Researchers Say

In general, newer antidepressants tend to be better tolerated due to fewer side effects, while the most effective drug in terms of reducing depressive symptoms was amitriptyline -- a drug first discovered in the 1950s.

Reuters: Study Seeks To End Antidepressant Debate-The Drugs Do Work

A vast research study that sought to settle a long-standing debate about whether or not anti-depressant drugs really work has found they are indeed effective in relieving acute depression in adults. The international study - a meta-analysis pooling results of 522 trials covering 21 commonly-used antidepressants and almost 120,000 patients - uncovered a range of outcomes, with some drugs proving more effective than others and some having fewer side effects. (Kelland, 2/22)

Modern Healthcare: Treatment-Resistant Depression Doubles Patient Healthcare Costs

Patients with major depression that is difficult to treat with traditional antidepressants have higher average costs for mental healthcare and non-mental healthcare compared with those who do respond to medication, and researchers say more should be done to curb those costs. A study published in the Journal of Clinical Psychiatry on Wednesday found that roughly 16% of patients with major depression have a treatment-resistant form of the disorder and do not respond to two or more antidepressants. That can cost an average of more than $17,000 per year in healthcare expenditures, compared with $9,700 among non-treatment-resistant-depression patients. (Johnson, 2/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 2
  • Wednesday, July 1
  • Tuesday, June 30
  • Monday, June 29
  • Friday, June 26
  • Thursday, June 25
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF